The Global TIL Therapy Market is driven by growing cancer prevalence
Tumor-infiltrating lymphocyte (TIL) therapy involves extracting immune cells from a patient's tumor and growing them in the laboratory. These TILs are then infused back into the patient to help recognize and destroy cancer cells. TIL therapy is emerging as an effective immunotherapy approach for certain types of cancers, especially melanoma. It works by harvesting a patient's own immune cells, known as T cells or lymphocytes, from a sample of their tumor. These cells are then isolated and grown in the lab to increase their number. Once expanded, the TILs are infused back into the patient through an intravenous line. The TILs target and kill cancer cells throughout the body while leaving normal cells unharmed.
The Global TIL Therapy Market is estimated to be valued at USD 0.092 Billion in 2024 and is expected to reach USD 9.20 Billion by 2031, growing at a compound annual growth rate (CAGR) of 39.3% from 2024 to 2031.
The key driver fueling the Global TIL Therapy Market growth is the rising burden of cancer worldwide. According to the WHO, cancer incidences are expected to rise by over 70% in the next 20 years. Additionally, the growing popularity of immunotherapy coupled with the advantages of TIL therapy over conventional treatment modalities such as chemotherapy are propelling the adoption of TIL therapy. The capability of TIL therapy to enhance patient survival rates with fewer side effects compared to other options is furthering its demand. Besides, increasing R&D investments by both private and public players for developing advanced TIL therapy products are supporting the market expansion.
Get More Insights on- Global TIL Therapy Market
Get This Report in Japanese Language: 世界のTIL療法市場
Get This Report in Korean Language: 글로벌 TIL 치료 시장
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian